DanCann Pharma A/S Completes Issuance (8) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2
COPENHAGEN, Denmark, 10 January 2024 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, has today, on 10 January 2024, issued a total of 24,999,999 new shares of nominally DKK 0.0375 each by conversion of debt in the total amount of DKK 500,000 under the instrument issued as of 13 July 2023.As set out in press release published on 17 July 2023, the Company has issued a total of 378 convertible debt instruments, each of an amount of DKK 50,000, equal to an aggregate amount of DKK 18,900,000, and 8,190,000 warrants to Nordic Growth